Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories (ABT) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Abbott is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good ind ...

The stock of healthcare behemoth Abbott Laboratories (NYSE: ABT ) has experienced an uninspiring 2024 so far; in a year where the prime equity bellwether has generated solid returns of 23%, and even the healthcare cohort of the S&P 500Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati ...

Core Viewpoint - Abbott Laboratories is expected to report Q3 2024 results on October 16, with projected revenue of $10.6 billion and earnings of $1.20 per share, in line with market expectations [1] Revenue and Earnings Summary - The company anticipates a mid-single-digit revenue increase driven by higher sales of FreeStyle Libre [1] - Abbott's Q2 2024 revenue was $10.4 billion, reflecting a 4% year-over-year growth, with medical devices up 10.2%, nutrition up 3.5%, and established pharmaceuticals up 0.6% [3] - The company expects total 2024 revenue to rise by 9.5% to 10% on an organic basis [3] Segment Performance - The Nutrition segment is expected to benefit from market share gains in baby formula products [2] - Medical devices are projected to see increased sales due to higher procedure volumes and demand for diabetes products, particularly FreeStyle Libre [2] - Abbott's COVID-19 testing sales were $305 million in Q3 2023, but this figure is expected to decline in Q3 2024, slightly offsetting growth in core laboratory diagnostics [2] Margin and Profitability - A slight rise in pre-tax margins is anticipated, contributing to bottom-line growth [2] - In Q2 2024, Abbott's adjusted pre-tax income margin expanded by 64 basis points year-over-year to 22.7% [3] Stock Valuation and Performance - Abbott's stock is considered fairly priced at $116, with an estimated valuation of $119 per share, based on a P/E ratio of 25 times expected earnings of $4.68 per share in 2024 [4] - The stock has shown volatility similar to the S&P 500, with expectations of sideways trading in the near term [4][5]

In its upcoming report, Abbott (ABT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting an increase of 5.3% compared to the same period last year. Revenues are forecasted to be $10.56 billion, representing a year-over-year increase of 4.1%.The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial est ...

Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA SystemGlobal FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration clearance, begins commercial launchABBOTT PARK, Ill., Oct. 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solut ...

The market expects Abbott (ABT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying ABT stock? Here's what analysts think: B Read More: ...

Abbott (ABT) closed the most recent trading day at $113.64, moving +0.07% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.01%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.08%. The maker of infant formula, medical devices and drugs's shares have seen a decrease of 0.96% over the last month, surpassing the Medical sector's loss of 3.6% and falling behind the S&P 500's gain of 1.21%. Investors will be eagerly watching for th ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Abbott (ABT) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.When looking at the last two reports, this maker of infant formula, medical devices and drugs has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 2.86%, on average, in the last two quarters.For the ...

Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.Investing in dividend stocks is one of the best and easiest ways to generate excellent returns over the long run, particularly if you pick those with reliable histories of payout hikes.Companies that can regularly boost their payouts over the long term generally have solid underlying businesses. Moreover, reinvesting your dividends can significantly boost your total returns over time. Despite these ben ...